FDA ODE II Overhaul Continues: Rarick Returns, Sobel Moves Up
Executive Summary
FDA is completing a change of the guard in the Office of Drug Evaluation II with the appointment of Reproductive & Urologic Drug Products Division Director Lisa Rarick, MD, as ODE II deputy director.
You may also be interested in...
RU-486 Action Date Is Sept. 30; Allen Named Reproductive Division Director
The Population Council anticipates FDA action on its pending mifepristone NDA by Sept. 30.
RU-486 Action Date Is Sept. 30; Allen Named Reproductive Division Director
The Population Council anticipates FDA action on its pending mifepristone NDA by Sept. 30.
FDA And EMEA To Compare Regulatory Approaches Used In 1998 NME Cohort
FDA and the European Medicines Evaluation Agency will conduct a joint assessment of the approaches used by the two agencies in the 1998 cohort of new molecular entity reviews.